Enavogliflozin is a selective inhibitor of SGLT2, developed as an active pharmaceutical ingredient for use in research and pharmaceutical manufacturing related to diabetes and obesity.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1415472-28-4
TL-895
pharmaceutical raw material
Dronedarone hydrochloride
pharmaceutical raw material
Dronedarone
pharmaceutical raw material
(2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone
pharmaceutical raw material
(2S,3R,4R,5S,6R)-2-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol
KORCWPOBTZTAFI-YVTYUBGGSA-N
C1CC1C2=CC=C(C=C2)CC3=CC(=C4CCOC4=C3Cl)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O